Zenolution Signs Joint Clinical Research Agreement on COVID-19 with Gangnam Bedro Hospital

[Asia Economy Reporter Lee Gwan-ju] Genolution announced on the 16th that it has signed a joint research contract with Gangnam Bedro Hospital for genotype analysis of clinical patients confirmed with COVID-19.

Under this contract, genotype analysis of the virus (SARS-CoV-2) from COVID-19 confirmed patients will be conducted using the next-generation sequencing (NGS) method developed by Genolution. The study will not only identify the genetic characteristics of the infecting virus according to the patient's age, symptoms, and vaccination status but also investigate the correlations between viral mutations and the types of treatments, treatment methods, and treatment effectiveness.

Using NGS allows for the analysis of the entire genome of the coronavirus, enabling detection of all known mutations as well as newly emerged recombinant mutations and previously unknown variants.

A Genolution representative stated, "Based on the NGS technology recognized through long-term research, we will successfully carry out this joint clinical study. We will also accelerate the development of NGS-based test kits and automated equipment currently under development, aiming for commercialization within this year, and expand our next-generation molecular diagnostics business through various genetic tests."